{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:34:47Z","timestamp":1767854087456,"version":"3.49.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011819","name":"Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["22784"],"award-info":[{"award-number":["22784"]}],"id":[{"id":"10.13039\/501100011819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.biopha.2021.111544","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T22:55:18Z","timestamp":1617231318000},"page":"111544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach"],"prefix":"10.1016","volume":"138","author":[{"given":"Zahra","family":"Molavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Razi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Amir","family":"Mirmotalebisohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirjafar","family":"Adibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzieh","family":"Sameni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshid","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Niknam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Aliashrafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soudeh","family":"Ghafouri-Fard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Jeibouei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soodeh","family":"Mahdian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakimeh","family":"Zali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Mehdi","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2021.111544_bib2","article-title":"SARS-CoV-2 and COVID-19: between pathophysiology complexity and therapeutic uncertainty","author":"Romagnoli","year":"2020","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2021.111544_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005531","article-title":"Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor","volume":"12","author":"Kim","year":"2016","journal-title":"PLoS Pathog."},{"issue":"22","key":"10.1016\/j.biopha.2021.111544_bib4","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"te Velthuis","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2021.111544_bib5","series-title":"Coronavirus Main Proteinase: Target for Antiviral Drug Therapy, Coronaviruses with Special Emphasis on First Insights Concerning SARS","first-page":"173","author":"Anand","year":"2005"},{"key":"10.1016\/j.biopha.2021.111544_bib6","first-page":"1","article-title":"Identification of chymotrypsin-like protease inhibitors of SARS-Cov-2 via integrated computational approach","author":"Khan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL M pro active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.111544_bib8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.111544_bib9","doi-asserted-by":"crossref","unstructured":"Y.-C. Chang, Y.-A. Tung, K.-H. Lee, T.-F. Chen, Y.-C. Hsiao, H.-C. Chang, T.-T. Hsieh, C.-H. Su, S.-S. Wang, J.-Y. Yu, Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking, 2020.","DOI":"10.20944\/preprints202002.0242.v1"},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2021.111544_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04502","article-title":"SARS-CoV-2 RNA dependent RNA polymerase (RdRp)\u2013a drug repurposing study","volume":"6","author":"Ahmad","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2021.111544_bib12","unstructured":"T.U.o.H. Kong, Lopinavir\/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment, 2020."},{"key":"10.1016\/j.biopha.2021.111544_bib13","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.111544_bib14","unstructured":"B. Pharmaceuticals, A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19, 2020."},{"key":"10.1016\/j.biopha.2021.111544_bib15","unstructured":"Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS), 2020."},{"key":"10.1016\/j.biopha.2021.111544_bib16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/cells9040920","article-title":"scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, Leydig and Sertoli cells","volume":"9","author":"Wang","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.biopha.2021.111544_bib17","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2021.111544_bib18","article-title":"Lack of antiviral activity of darunavir against SARS-CoV-2","author":"De Meyer","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2021.111544_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000Research"},{"issue":"3","key":"10.1016\/j.biopha.2021.111544_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/tmi.13383","article-title":"The COVID\u201019 epidemic","volume":"25","author":"Velavan","year":"2020","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.biopha.2021.111544_bib21","doi-asserted-by":"crossref","unstructured":"S. Nabirotchkin, A.E. Peluffo, J. Bouaziz, D. Cohen, Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19, 2020.","DOI":"10.20944\/preprints202003.0302.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib22","article-title":"Lopinavir\/ritonavir for the treatment of COVID-19: a living systematic review protocol","author":"Verdugo-Paiva","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2021.111544_bib23","article-title":"Therapeutic management of patients with COVID-19: a systematic review","volume":"2","author":"Tobaiqy","year":"2020","journal-title":"Infect. Prev. Pract."},{"key":"10.1016\/j.biopha.2021.111544_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40200-020-00546-9","article-title":"Drug repurposing using computational methods to identify therapeutic options for COVID-19","volume":"19","author":"Mahdian","year":"2020","journal-title":"J. Diabetes Metab. Disord."},{"issue":"23\u201324","key":"10.1016\/j.biopha.2021.111544_bib25","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.drudis.2010.10.003","article-title":"PubChem as a public resource for drug discovery","volume":"15","author":"Li","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Chemin."},{"issue":"5","key":"10.1016\/j.biopha.2021.111544_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/qua.25512","article-title":"A sobering assessment of small\u2010molecule force field methods for low energy conformer predictions","volume":"118","author":"Kanal","year":"2018","journal-title":"Int. J. Quantum Chem."},{"issue":"2","key":"10.1016\/j.biopha.2021.111544_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/bib\/2.2.195","article-title":"Swiss-PDB viewer (deep view)","volume":"2","author":"Kaplan","year":"2001","journal-title":"Brief. Bioinform."},{"issue":"13","key":"10.1016\/j.biopha.2021.111544_bib29","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111544_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jsb.2011.09.006","article-title":"UCSF Chimera, MODELLER, and IMP: an integrated modeling system","volume":"179","author":"Yang","year":"2012","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.biopha.2021.111544_bib31","doi-asserted-by":"crossref","unstructured":"T. Chowdhury, G. Roymahapatra, S.M. Mandal, In silico identification of a potent arsenic based approved drug darinaparsin against SARS-CoV-2: inhibitor of RNA dependent RNA polymerase (RdRp) and necessary proteases, 2020.","DOI":"10.26434\/chemrxiv.12200495.v1"},{"issue":"2","key":"10.1016\/j.biopha.2021.111544_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12551-016-0247-1","article-title":"Software for molecular docking: a review","volume":"9","author":"Pagadala","year":"2017","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.biopha.2021.111544_bib33","series-title":"Chemical Biology","first-page":"243","article-title":"Small-molecule library screening by docking with PyRx","author":"Dallakyan","year":"2015"},{"issue":"8","key":"10.1016\/j.biopha.2021.111544_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012029","article-title":"Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing","volume":"5","author":"Patil","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2021.111544_bib35","series-title":"Discovery Studio Modeling Environment, Release 3.5, Accelrys Discovery Studio","author":"Inc","year":"2012"},{"key":"10.1016\/j.biopha.2021.111544_bib36","first-page":"1","article-title":"Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations","author":"Mosquera-Yuqui","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"9","key":"10.1016\/j.biopha.2021.111544_bib37","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1021\/ct300400x","article-title":"Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone \u03d5, \u03c8 and side-chain \u03c71 and \u03c72 dihedral angles","volume":"8","author":"Best","year":"2012","journal-title":"J. Chem. Theory Comput."},{"issue":"12","key":"10.1016\/j.biopha.2021.111544_bib38","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1021\/ct200196m","article-title":"An automated force field topology builder (ATB) and repository: version 1.0","volume":"7","author":"Malde","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.biopha.2021.111544_bib39","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2021.111544_bib40","first-page":"1","article-title":"Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2\u2032-O-ribose methyltransferase","author":"Khan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2021.111544_bib41","doi-asserted-by":"crossref","unstructured":"Y. Kumar, H. Singh, In silico identification and docking-based drug repurposing against the main protease of SARS-CoV-2, causative agent of COVID-19, 2020.","DOI":"10.26434\/chemrxiv.12049590.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib42","doi-asserted-by":"crossref","unstructured":"K. Mohamed, N. Yazdanpanah, A. Saghazadeh, N. Rezaei, Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review, Available at SSRN 3583748, 2020.","DOI":"10.2139\/ssrn.3583748"},{"key":"10.1016\/j.biopha.2021.111544_bib43","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","article-title":"Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study","volume":"60","author":"Wang","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.biopha.2021.111544_bib44","unstructured":"F. da Silveira Silva, B. Brixner, C.F. de Oliveira, J.D.P. Renner, What are the risk factors and agents responsible for bacterial infections in ICUs?"},{"issue":"10223","key":"10.1016\/j.biopha.2021.111544_bib45","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2021.111544_bib46","first-page":"145","article-title":"Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome","volume":"202","author":"Bhatia","year":"2004","journal-title":"J. Pathol. J. Pathol. Soc. G. B. Irel."},{"issue":"D1","key":"10.1016\/j.biopha.2021.111544_bib47","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2021.111544_bib48","doi-asserted-by":"crossref","unstructured":"S. Adem, V. Eyupoglu, I. Sarfraz, A. Rasul, M. Ali, Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope against CORONA, 2020.","DOI":"10.20944\/preprints202003.0333.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib49","first-page":"1","article-title":"Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach","author":"Mittal","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2021.111544_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1763201","article-title":"An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study","author":"Das","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2021.111544_bib51","doi-asserted-by":"crossref","unstructured":"R.Y. Utomo, E. Meiyanto, Revealing the potency of citrus and galangal constituents to halt SARS-CoV-2 infection, 2020.","DOI":"10.20944\/preprints202003.0214.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib52","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2021.111544_bib53","unstructured":"L. Cheng, W. Zheng, M. Li, J. Huang, S. Bao, Q. Xu, Z. Ma, Citrus fruits are rich in flavonoids for immunoregulation and potential targeting ACE2, 2020."},{"key":"10.1016\/j.biopha.2021.111544_bib54","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1038\/srep07237","article-title":"A dual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways","volume":"4","author":"Dong","year":"2014","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2021.111544_bib55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF03259516","article-title":"The use of antiallergic and antiasthmatic drugs in viral infections of the upper respiratory tract","volume":"6","author":"\u00c5berg","year":"1996","journal-title":"Clin. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2332\/allergolint.55.35","article-title":"Recent advances in the development of anti-allergic drugs","volume":"55","author":"Nagai","year":"2006","journal-title":"Allergol. Int."},{"key":"10.1016\/j.biopha.2021.111544_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109828","article-title":"As a potential treatment of COVID-19: Montelukast","volume":"142","author":"Fidan","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.biopha.2021.111544_bib58","article-title":"The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15","author":"Matsuyama","year":"2020","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.biopha.2021.111544_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-200241020-00003","article-title":"Pharmacokinetic profile of zafirlukast","volume":"41","author":"Dekhuijzen","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/irv.12334","article-title":"The therapeutic effects of sodium cromoglycate against influenza A virus H5N1 in mice","volume":"10","author":"Han","year":"2016","journal-title":"Influenza Other Respir. Virus"},{"key":"10.1016\/j.biopha.2021.111544_bib61","doi-asserted-by":"crossref","unstructured":"U. Shankar, N. Jain, P. Majee, S.K. Mishra, B. Rathi, A. Kumar, Potential drugs targeting Nsp16 protein may corroborates a promising approach to combat SARS-CoV-2 virus, 2020.","DOI":"10.26434\/chemrxiv.12279671.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamacardio.2020.1105","article-title":"Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality","volume":"5","author":"Bonow","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.biopha.2021.111544_bib63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.biopha.2021.111544_bib64","doi-asserted-by":"crossref","unstructured":"A. Sajib, Repurposing of approved drugs with potential to block SARS-CoV-2 surface glycoprotein interaction with host receptor, 2020.","DOI":"10.20944\/preprints202004.0369.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib65","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","article-title":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors\u2014lessons from available evidence and insights into COVID-19","volume":"43","author":"Kai","year":"2020","journal-title":"Hypertens. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/cells9010031","article-title":"The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation","volume":"9","author":"Vogel","year":"2019","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.biopha.2021.111544_bib67","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/bloodadvances.2020001669","article-title":"Promoting platelets is a therapeutic option to combat severe viral infection of the lung","volume":"4","author":"Qiu","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2021.111544_bib68","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.111544_bib69","article-title":"Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics!Abstract","author":"Arshad","year":"2020","journal-title":"medRxiv"},{"issue":"18","key":"10.1016\/j.biopha.2021.111544_bib70","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.111544_bib71","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/jth.14781","article-title":"Disseminated intravascular coagulation in patients with 2019\u2013nCoV pneumonia","volume":"18","author":"Lillicrap","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.biopha.2021.111544_bib72","article-title":"Ticagrelor can be an important agent in the treatment of severe COVID-19 patients with myocardial infarction","volume":"37","author":"Ak\u015fit","year":"2020","journal-title":"Balk. Med. J."},{"issue":"3","key":"10.1016\/j.biopha.2021.111544_bib73","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11060-008-9789-9","article-title":"Cerebral astroblastoma: analysis of six cases and critical review of treatment options","volume":"93","author":"Salvati","year":"2009","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.biopha.2021.111544_bib74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clineuro.2014.07.013","article-title":"Astroblastoma: report of two cases with unexpected clinical behavior and review of the literature","volume":"125","author":"Janz","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"02","key":"10.1016\/j.biopha.2021.111544_bib75","doi-asserted-by":"crossref","first-page":"CNS13","DOI":"10.2217\/cns-2017-0038","article-title":"Patterns of care and treatment outcomes of patients with astroblastoma: a National Cancer Database analysis","volume":"7","author":"Merfeld","year":"2018","journal-title":"CNS Oncol."},{"key":"10.1016\/j.biopha.2021.111544_bib76","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.14871","article-title":"Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID\u201019 respiratory syndrome patients treated with antiviral agents: the Cremona experience","volume":"18","author":"Testa","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.biopha.2021.111544_bib77","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/ml300112e","article-title":"Monitoring the distribution of warfarin in blood plasma","volume":"3","author":"Rosengren","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2021.111544_bib78","doi-asserted-by":"crossref","unstructured":"M. Hosseini, W. Chen, C. Wang, Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs, 2020.","DOI":"10.26434\/chemrxiv.12237995.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib79","doi-asserted-by":"crossref","unstructured":"A. Chernyshev, Pharmaceutical targeting the envelope protein of SARS-CoV-2: the screening for inhibitors in approved drugs, 2020.","DOI":"10.26434\/chemrxiv.12286421.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib80","doi-asserted-by":"crossref","unstructured":"A. Gupta, Profiling molecular simulations of SARS-CoV-2 main protease (Mpro) binding to repurposed drugs using neural network force fields, 2020.","DOI":"10.26434\/chemrxiv.12376094.v3"},{"key":"10.1016\/j.biopha.2021.111544_bib81","doi-asserted-by":"crossref","unstructured":"K. Sharma, S. Morla, A. Goyal, S. Kumar, Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2, 2020.","DOI":"10.26434\/chemrxiv.12111138.v1"},{"key":"10.1016\/j.biopha.2021.111544_bib82","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.micinf.2020.03.003","article-title":"Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2","volume":"22","author":"Qiu","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.biopha.2021.111544_bib83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mce.2009.12.022","article-title":"Androgen receptor and androgen-dependent gene expression in lung","volume":"317","author":"Mikkonen","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2021.111544_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13535","article-title":"Effects of 5\u2013alpha reductase inhibitors on lung function: a reason for discontinuation during COVID\u201019 pandemic?","volume":"33","author":"Kroumpouzos","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2021.111544_bib85","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.111544_bib86","article-title":"Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2in vitroand SARS-CoVin vivo!Abstract","author":"Weston","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2021.111544_bib87","article-title":"In silico identification of widely used and well tolerated drugs that may inhibit SARSCov-2 3C-like protease and viral RNA-dependent RNA polymerase activities, and may have potential to be directly used in clinical trials","author":"Gul","year":"2020","journal-title":"Chemrxiv"},{"key":"10.1016\/j.biopha.2021.111544_bib88","article-title":"Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19","author":"Vatansever","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2021.111544_bib89","article-title":"Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for combating COVID19","author":"Mevada","year":"2020","journal-title":"ChemRxiv"},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1152\/japplphysiol.00094.2009","article-title":"Role of calcitonin gene-related peptide (CGRP) in ovine burn and smoke inhalation injury","volume":"107","author":"Lange","year":"2009","journal-title":"J. Appl. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/123.1.9","article-title":"Ergotamine in the acute treatment of migraine: a review and European consensus","volume":"123","author":"Tfelt-Hansen","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2021.111544_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116832","article-title":"Central nervous system manifestations of COVID-19: a systematic review","volume":"413","author":"Asadi-Pooya","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.biopha.2021.111544_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108125","article-title":"COVID-19 and diabetes: can DPP4 inhibition play a role?","volume":"162","author":"Iacobellis","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2021.111544_bib94","article-title":"Fatal toxicity of chloroquine or hydroxychloroquine with metformin in mice","author":"Rajeshkumar","year":"2020","journal-title":"Biorxiv"},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib95","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/jpet.111.191098","article-title":"The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob\/ob mice","volume":"342","author":"Sch\u00fcrmann","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2021.111544_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3330","article-title":"DPP4 inhibition: preventing SARS\u2010CoV\u20102 infection and\/or progression of COVID\u201019?","volume":"36","author":"Strollo","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.biopha.2021.111544_bib97","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00592-020-01539-z","article-title":"Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19","volume":"57","author":"Solerte","year":"2020","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.biopha.2021.111544_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108216","article-title":"Is DPP4 inhibition a comrade or adversary in COVID-19 infection","volume":"164","author":"Dalan","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2021.111544_bib99","article-title":"Letter to the Editor in response to the article \u201cCOVID-19 and diabetes: can DPP4 inhibition play a role?\u201d","author":"Males","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"10","key":"10.1016\/j.biopha.2021.111544_bib100","first-page":"5197","article-title":"The impact of heroin illicit market in the framework of COVID 19 pandemic","volume":"24","author":"Marinelli","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.111544_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140995","article-title":"Understanding heroin overdose: a study of the acute respiratory depressant effects of injected pharmaceutical heroin","volume":"10","author":"Jolley","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/y86-001","article-title":"The therapeutic use of heroin: a review of the pharmacological literature","volume":"64","author":"Sawynok","year":"1986","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111544_bib103","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00000441-194621150-00003","article-title":"Rutin: a new drug for the treatment of increased capillary fragility","volume":"211","author":"Shanno","year":"1946","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.biopha.2021.111544_bib104","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ddr.21679","article-title":"Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID\u201019","volume":"81","author":"Rothlin","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.biopha.2021.111544_bib105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS\u2010CoV\u20102 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1620\/tjem.241.45","article-title":"Combination therapy with ombitasvir\/paritaprevir\/ritonavir for dialysis patients infected with hepatitis C virus: a prospective multi-institutional study","volume":"241","author":"Sato","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.biopha.2021.111544_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104419","article-title":"Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein","volume":"85","author":"Feng","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111544_bib108","doi-asserted-by":"crossref","first-page":"236","DOI":"10.6026\/97320630016236","article-title":"Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus","volume":"16","author":"Odhar","year":"2020","journal-title":"Bioinformation"},{"key":"10.1016\/j.biopha.2021.111544_bib109","article-title":"In silico identification of widely used and well tolerated drugs that may inhibit SARSCov-2 3C-like protease and viral RNA-dependent RNA polymerase activities, and may have potential to be directly used in clinical trials","author":"Gul","year":"2020","journal-title":"ChemRxiv"},{"issue":"1","key":"10.1016\/j.biopha.2021.111544_bib110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/cells9010031","article-title":"The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation","volume":"9","author":"Vogel","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.biopha.2021.111544_bib111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/medicina49110073","article-title":"Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis","volume":"49","author":"Silkauskaite","year":"2013","journal-title":"Medicina"},{"issue":"6","key":"10.1016\/j.biopha.2021.111544_bib112","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.14871","article-title":"Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID\u201019 respiratory syndrome patients treated with antiviral agents: the Cremona experience","volume":"18","author":"Testa","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2021.111544_bib113","series-title":"Factor Xa Inhibition Reduces Coagulation Activity but Not Inflammation Among People with HIV: A Randomized Clinical Trial, Open Forum Infectious Diseases","first-page":"ofaa026","author":"Baker","year":"2020"},{"key":"10.1016\/j.biopha.2021.111544_bib114","article-title":"Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2","author":"Anwar","year":"2020","journal-title":"ChemRxiv"},{"key":"10.1016\/j.biopha.2021.111544_bib115","unstructured":"S. Weston, R. Haupt, J. Logue, K. Matthews, M.J.B. Frieman, FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro, 2020."},{"key":"10.1016\/j.biopha.2021.111544_bib116","doi-asserted-by":"crossref","unstructured":"J. Dyall, C.M. Coleman, B.J. Hart, T. Venkataraman, M.R. Holbrook, J. Kindrachuk, R.F. Johnson, G.G. Olinger, P.B. Jahrling, M.J. Laidlaw, Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection, 58 (8) (2014) 4885\u20134893.","DOI":"10.1128\/AAC.03036-14"},{"key":"10.1016\/j.biopha.2021.111544_bib117","unstructured":"E.C. Vatansever, K. Yang, K.C. Kratch, A. Drelich, C.-C. Cho, D.M. Mellot, S. Xu, C.-T.K. Tseng, W.R.J.b. Liu, Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19, 2020."},{"key":"10.1016\/j.biopha.2021.111544_bib118","doi-asserted-by":"crossref","unstructured":"V. Mevada, P. Dudhagara, H. Gandhi, N. Vaghamshi, U. Beladiya, R. Patel, Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for combating COVID19, 2020.","DOI":"10.26434\/chemrxiv.12115251.v1"},{"issue":"5","key":"10.1016\/j.biopha.2021.111544_bib119","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/add.14870","article-title":"Prevalence of respiratory conditions among people who use illicit opioids: a systematic review","volume":"115","author":"Hulin","year":"2020","journal-title":"Addiction"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221003292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221003292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:32:09Z","timestamp":1760099529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221003292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":119,"alternative-id":["S0753332221003292"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111544","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111544"}}